期刊
CELLS
卷 9, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/cells9122560
关键词
atherosclerosis; vaccination; immunization; low-density lipoprotein (LDL); apolipoprotein B (ApoB); antigen-specific; regulatory T cells (T-regs); antibodies
类别
资金
- Deutsche Forschungsgemeinschaft [SFB TRR259 (397484323)]
- Neven-DuMont foundation
- Koeln Fortune Program [363/2020]
Atherosclerosis is the major underlying pathology of cardiovascular diseases that together are the leading cause of death worldwide. The formation of atherosclerotic plaques is driven by chronic vascular inflammation. Although several risk factors have been identified and significant progress in disease prevention and treatment has been made, no therapeutic agents targeting inflammation are clinically available. Recent clinical trials established the potential of anti-inflammatory therapies as a treatment of atherosclerosis. However, adverse impacts on host defense have raised safety concerns about these therapies. Scientific evidence during the past 40 years implicated an adaptive immune response against plaque-associated autoantigens in atherogenesis. Preclinical data have underscored the protective potential of immunization against such targets precisely and without the impairment of host defense. In this review, we discuss the current vaccination strategies against atherosclerosis, supposed mechanisms of action, therapeutic potential, and the challenges that must be overcome in translating this idea into clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据